Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Development of New Therapies for Severe Asthma.

Fajt ML, Wenzel SE.

Allergy Asthma Immunol Res. 2017 Jan;9(1):3-14. doi: 10.4168/aair.2017.9.1.3. Review.

2.

Beyond Genetics-Stratified and Personalised Medicines Using Multiple Parameters.

Peck R, Smith P.

Pharmaceuticals (Basel). 2010 May 25;3(5):1637-1651. Review.

3.

Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.

Caminati M, Senna G, Stefanizzi G, Bellamoli R, Longhi S, Chieco-Bianchi F, Guarnieri G, Tognella S, Olivieri M, Micheletto C, Festi G, Bertocco E, Mazza M, Rossi A, Vianello A; North East Omalizumab Network study group..

BMC Pulm Med. 2016 Aug 25;16(1):128. doi: 10.1186/s12890-016-0290-5.

4.

The immunology of asthma: Asthma phenotypes and their implications for personalized treatment.

Borish L.

Ann Allergy Asthma Immunol. 2016 Aug;117(2):108-14. doi: 10.1016/j.anai.2016.04.022. Review.

PMID:
27499537
5.

Alternative splicing of interleukin-33 and type 2 inflammation in asthma.

Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz-Scroggins ME, Peters MC, Wesolowska-Andersen A, Gonzalez JR, MacLeod HJ, Christian LS, Yuan S, Barry L, Woodruff PG, Ansel KM, Nocka K, Seibold MA, Fahy JV.

Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8765-70. doi: 10.1073/pnas.1601914113.

6.

The Therapeutic Potential of Targeting Cytokine Alarmins to Treat Allergic Airway Inflammation.

Sy CB, Siracusa MC.

Front Physiol. 2016 Jun 14;7:214. doi: 10.3389/fphys.2016.00214. Review.

7.

Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases.

Oettgen HC.

J Allergy Clin Immunol. 2016 Jun;137(6):1631-45. doi: 10.1016/j.jaci.2016.04.009. Review.

PMID:
27263999
8.

Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study.

Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M, Zhong N; China Omalizumab Study Group..

Allergy Asthma Immunol Res. 2016 Jul;8(4):319-28. doi: 10.4168/aair.2016.8.4.319.

9.

Asthma Was Talking, But We Weren't Listening. Missed or Ignored Signals That Have Slowed Treatment Progress.

Fahy JV.

Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S78-82. doi: 10.1513/AnnalsATS.201508-515MG.

PMID:
27027957
10.

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.

Zafari Z, Sadatsafavi M, Marra CA, Chen W, FitzGerald JM.

PLoS One. 2016 Jan 11;11(1):e0146003. doi: 10.1371/journal.pone.0146003.

12.

Cutaneous sarcoidosis in a patient with severe asthma treated with omalizumab.

Yung S, Han D, Lee JK.

Can Respir J. 2015 Nov-Dec;22(6):315-6.

13.

Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.

Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y, Cao C, Ying S, Chen Z, Li W, Wu B, Shen H.

Sci Rep. 2015 Feb 3;5:8191. doi: 10.1038/srep08191. Review. Erratum in: Sci Rep. 2015;5:9548.

14.

Type 2 inflammation in asthma--present in most, absent in many.

Fahy JV.

Nat Rev Immunol. 2015 Jan;15(1):57-65. doi: 10.1038/nri3786. Review.

15.

Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy.

Hendeles L, Khan YR, Shuster JJ, Chesrown SE, Abu-Hasan M.

Ann Allergy Asthma Immunol. 2015 Jan;114(1):58-62.e2. doi: 10.1016/j.anai.2014.10.012.

16.

Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.

Huffaker MF, Phipatanakul W.

Immunol Allergy Clin North Am. 2015 Feb;35(1):129-44. doi: 10.1016/j.iac.2014.09.005. Review.

17.

Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation.

Skiepko R, Ziętkowski Z, Lukaszyk M, Budny W, Skiepko U, Milewski R, Bodzenta-Łukaszyk A.

Postepy Dermatol Alergol. 2014 Oct;31(5):305-9. doi: 10.5114/pdia.2014.40973.

18.

Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.

Braunstahl GJ, Canvin J, Peachey G, Chen CW, Georgiou P.

Biol Ther. 2014 Dec;4(1-2):57-67. doi: 10.1007/s13554-014-0019-z.

19.

Diagnosis and management of eosinophilic asthma: a US perspective.

Walford HH, Doherty TA.

J Asthma Allergy. 2014 Apr 11;7:53-65. doi: 10.2147/JAA.S39119. Review.

20.

Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review.

D'Amato G, Stanziola A, Sanduzzi A, Liccardi G, Salzillo A, Vitale C, Molino A, Vatrella A, D'Amato M.

Multidiscip Respir Med. 2014 Apr 15;9(1):23. doi: 10.1186/2049-6958-9-23. Review.

Items per page

Supplemental Content

Support Center